MarketPulse

dry eye disease

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Aldeyra Plunges 71% on Failed Trial Disclosure; Securities Lawsuit Deadline Looms

Aldeyra Therapeutics faces federal securities lawsuit alleging inadequate disclosure of failed clinical trial results for reproxalap. Stock crashed 71% after FDA rejection; investor deadline May 29, 2026.
ALDXsecurities class actionstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Gears Up for Pivotal 2026 With Six Major Clinical Readouts Planned

Oculis announces investor conference participation ahead of landmark 2026 featuring multiple drug readouts and regulatory designations across three lead programs.
OCSOCSAWclinical trialsbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

ALDX Stock Crashes 71% After FDA Rejects Lead Drug; Class Action Lawsuit Filed

Aldeyra Therapeutics stock plummets 71% following FDA rejection of reproxalap for dry eye disease. Class action lawsuit filed; investor deadline May 29, 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson Fistel, Pllp

Aldeyra Stock Plummets 70% After FDA Rejection; Law Firm Eyes Securities Claims

Johnson Fistel investigates Aldeyra Therapeutics after FDA rejects lead drug reproxalap. Stock tumbles over 70% on March 17, 2026 announcement.
ALDXstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Harrow to Release 2025 Financial Results on March 2

Harrow Health will release 2025 financial results March 2, 2026, reaffirming $270-$280 million revenue guidance and highlighting its expanding pharmaceutical portfolio.
HROWfinancial resultsrevenue guidance